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short of incineration or boiling will be
effective. Furthermore, these results
suggest that temperatures achievable
in point-of-use hot water heaters
(household units) can deactivate
infectious B. procyonis eggs, thus pro-
viding an option for maintaining safe
drinking water during a possible event
of bioterrorism or a “boil water advi-
sory.” However, further efforts are
needed to determine the effectiveness
of heat and other disinfection methods
on inactivation of eggs in natural cir-
cumstances such as in feces or con-
taminated play areas including soil.
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Questioning
Aerosol
Transmission of
Influenza 
To the Editor: We have
reviewed the literature cited in
Tellier’s Review of Aerosol
Transmission of Influenza AVirus (1)
and disagree that it supports the con-
clusions drawn regarding the impor-
tance of aerosols in natural influenza
infection. In certain cited studies,
researchers recovered viable virus
from artificially generated aerosols;
this is not evidence that aerosol trans-
mission leads to natural human infec-
tion (2,3). By standard definitions,
the rarity of long-range infections
supports the conclusion that effective
aerosol transmission is absent in the
natural state (4) (www.cdc.gov/
ncidod/dhqp/gl_isolation_hicpac.
html). The superior efficacy of
inhaled versus intranasal zanamivir is
referenced as support for the idea that
the lower respiratory tract is the pre-
ferred site of influenza infection;
however, 1 study cited is insufficient-
ly powered, and the other 2 do not
compare the intranasal and inhaled
routes (5–7). The major site of depo-
sition of inhaled zanamivir is the
oropharynx (77.6%), not the lungs
(13.2%) (www.gsk.ca/en/products/
prescription/relenza_pm.pdf). In
another flawed study (8), study par-
ticipants naturally infected with wild-
type virus are compared with study
participants experimentally infected
with an attenuated strain.
In a review of such relevance,
critical analysis of confounding fac-
tors is necessary. The Alaska Airlines
outbreak (9) is presented as proof of
airborne influenza transmission; how-
ever, droplet/contact transmission
remains plausible because passenger
movement was not restricted and the
index patient was seated in high-traf-
fic area. In the Livermore Hospital
study (10), serious confounders such
as bed arrangements, number of
influenza exposures, patient mix, and
ventilation were not accounted for.
We encourage readers of Teller’s
article to review the relevant primary
literature. We believe that the only rea-
sonable conclusion that can be drawn
at this time is that aerosol transmission
does not play a major role in natural
influenza epidemiology. Whether
aerosols play any role in the transmis-
sion of influenza is a question
demanding an answer; it is clear that
we do not yet have that answer.
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In response: Coughing and
sneezing during influenza produce
virus-containing aerosols. In the labo-
ratory, influenza virus in homoge-
neous aerosols, free of large droplets,
can infect volunteers at very small
doses; studies of infectivity decay in
aerosols show persistence for hours.
These observations required the gen-
eration of artificial aerosols but were
performed under conditions that do
not enhance stability or virulence
(1,2). Therefore, they have great rele-
vance for natural infections.
The scarcity of infections that are
transmitted long range in well-venti-
lated areas does not rule out infectivi-
ty of aerosol-size particles near
patients. That only 13% of inhaled
zanamivir is deposited in the lungs is
not important: after inhalation, the
zanamivir concentration throughout
the respiratory tract is >10 µmol/L,
orders of magnitude above the 50%
inhibitory concentration (3). Intra-
nasal zanamivir is protective against
large droplets (4), which are trapped
in the nose (5). The requirement for
inhaled zanamivir in natural infec-
tions (6,7) points to aerosol contribu-
tion and to the lower respiratory tract
as the preferred site.
Little et al. (8) compared the
severity of natural illness caused by
H3N2 strains from 1974 and 1975 to
that caused by experimental intranasal
inoculation from H3N2 strains from
1972, 1974, and 1975. The challenge
strains underwent few passages; char-
acterizing them as “attenuated” is
incorrect. 
Although large droplets probably
accounted for some cases in the
Alaska Airlines outbreak (9), this out-
break was remarkable for its high
attack rate (72%) and for deficient
ventilation, which would increase
transmission by aerosols but not by
large droplets. Passengers with
influenza are common, yet with prop-
er ventilation such an attack rate is
uncommon.
During the Livermore Hospital
study (10), respiratory infections
other than influenza occurred in both
groups. It was assumed that visitors
and staff would provide equivalent
introductions of the virus during the
several months of the study; 4 study
participants in the irradiated building
seroconverted, but the virus did not
propagate. The concern by Lemieux
and colleagues about ventilation is
odd because it would affect mostly
aerosol transmission.
I concur with encouraging readers
to review the original references. They
make a compelling case for the impor-
tance of aerosol transmission. In con-
trast, no convincing data rule it out.
Raymond Tellier*
*Hospital for Sick Children, University of
Toronto, Toronto, Canada
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Parvoviruses
PARV4/5 in
Hepatitis C Virus–
infected Patient 
To the Editor: Parvoviruses are
small, nonenveloped DNA viruses
that infect both vertebrate and inverte-
brate hosts. Until recently, parvovirus
B19 and adeno-associated viruses,
which belong to the genera
Erythrovirus and  Dependovirus,
respectively, were the only known
members of the family Parvoviridae
that infected humans (1). However, 2
recent publications have identified 2
distinct, novel parvoviruses in
humans by using the DNase
sequence–independent single-primer
amplification technique and a related
method (2,3). The first of these virus-
es, termed PARV4, was observed in a
patient with symptoms of acute viral
infection syndrome after high-risk
behavior for infection with HIV-1,
although the patient was subsequently
confirmed as negative for HIV-1 (2).
The second parvovirus was identified
in respiratory samples from children
with lower respiratory tract infections
and termed human bocavirus (3).
Parvovirus B19 is a frequent con-
taminant of plasma pools that are used
in the manufacture of blood products,
which results in high viral loads in
pools and viral transmission in recipi-
ents of clotting factors (4). We identi-
fied PARV4 in such pools (5), albeit at
a lower frequency and titer than par-
vovirus B19, when parvovirus B19
was not excluded by screening with
nucleic acid amplification techniques.
Sequence analysis identified a second
genotype of PARV4, which we have
termed PARV5, that shares 92%
nucleotide identity with PARV4 (5).
PARV4 was originally identified
in a plasma sample from a homeless,
injection drug user with fatigue, night
sweats, pharyngitis, neck stiffness,
vomiting, diarrhea, arthralgia, and
confusion (2). This person was coin-
fected with hepatitis B virus. In this
study, we looked retrospectively for
PARV4 and PARV5 in blood samples
from a similar cohort of persons,
many of whom were known to be
infected with hepatitis C virus (HCV)
(as determined by the presence of
both HCV RNA and antibodies to
HCV), and some of whom were intra-
venous drug users (IVDUs) (6).
Blood samples were collected
from 26 cadavers in London and the
surrounding area as part of a study to
investigate the inhibition of nucleic
acid amplification techniques for
bloodborne viruses in tissue samples
(6). The cohort was composed of 10
HCV RNA–positive IVDUs, 8 HCV
RNA–positive non-IVDUs, 4 HCV
RNA–negative IVDUs, and 4 HCV
RNA–negative non-IVDUs (Table).
Nucleic acid was extracted as previ-
ously described (4) by using the
MagNA Pure LC instrument (Roche,
Basel, Switzerland). PCR was per-
formed with primers specific for the
second open reading frame (ORF2) in
the PARV4 genome (2), which is
homologous to the VP1 capsid of par-
vovirus B19. Primers PVORF2F (5′-
AGGAGCAGCAAACAAACTCA-
GAC-3′) and PVORF2R (5′-TCCTT-
CATCGCGGCTGTCACTAA-3′)
amplify a 268-bp region of ORF2
(nucleotides 2710–2977, GenBank
accession no. AY622943). The PCRs
were performed and analyzed as pre-
viously described (5). The assay is
highly specific (no cross-reactivity
with parvovirus B19) and sensitive
(detects 5–10 copies of PARV4 virus
DNA per reaction). 
PCR products were cloned,
sequenced, and compared with the
prototype PARV4. Two blood samples
were positive for PARV4, and a third
sample was positive for PARV5, with
99%–100% nucleotide identity. These
positive samples were from HCV
RNA–positive IVDUs (Table). The
titer of PARV4 and PARV5 DNA in
the positive samples was low and did
not exceed >700 copies/mL of plas-
ma, as determined by using a consen-
sus TaqMan assay (J. Fryer, unpub.
data). None of the other blood sam-
ples tested was positive for PARV4
and PARV5, including those for per-
sons who were HCV RNA negative
and not IVDUs.
In our previous study (5) of >130
fractionation pools (composed of
thousands of units from screened
healthy donors) for PARV4, the only
positive pools were from North
America and no European pools were
positive for PARV4 or PARV5. These
viruses may be present in such pools
but diluted to undetectable levels. In
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